Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment-Reference-Cited by-同舟云学术

Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment

Published:2021-10-26 Issue:16 Volume:326 Page:1627
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Anderson Timothy S.¹,Ayanian John Z.²³,Souza Jeffrey⁴,Landon Bruce E.⁴

Affiliation:

1. Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

2. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor

3. Editor, JAMA Health Forum

4. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2784225/jama_anderson_2021_ld_210060_1635192413.89509.pdf

Reference6 articles.

1. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility.;Alexander;JAMA,2021

2. Evaluation of Medicare claims data as a tool to identify dementia.;Lee;J Alzheimers Dis,2019

3. Centers for Medicare & Medicaid Services. Chronic Conditions Data Warehouse. Accessed July 10, 2021. https://www2.ccwdata.org/web/guest/condition-categories

4. ClinicalTrials.gov. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE). Accessed July 10, 2021. https://clinicaltrials.gov/ct2/show/NCT02484547

5. ClinicalTrials.gov. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE). Accessed July 10, 2021. https://clinicaltrials.gov/ct2/show/NCT02477800

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease;Acta Pharmaceutica Sinica B;2024-07

2. What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation;Mediators of Inflammation;2024-05-27

3. Incidence and Prevalence of Dementia: A 2015–2020 Population-Based Study in the Campania Region of Italy;Neuroepidemiology;2024-04-26

4. Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general population;2024-02-29

5. Individuals with dementia and populations with dementia;Cerebral Circulation - Cognition and Behavior;2024